SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that it has entered into a Captisol license agreement with SAGE Therapeutics, Inc. for the development and commercialization of Captisol-enabled® therapeutics for a broad range of debilitating central nervous system (CNS) conditions. Under the agreement, Ligand will receive upfront and research support payments, as well as potential milestone payments for Captisol-enabled programs. In addition to potentially receiving royalties on net sales for products that use the Captisol technology, Ligand will receive revenue from the sale of Captisol to Sage for clinical and commercial activities.
